Literature DB >> 20136718

Lactoferrin protects against concanavalin A-induced liver injury in mice.

Hao Yin1, Linling Cheng, Chapla Agarwal, Rajesh Agarwal, Cynthia Ju.   

Abstract

BACKGROUND: Liver diseases, caused by viral infection, autoimmune conditions, alcohol ingestion or the use of certain drugs, are a significant health issue, as many can develop into liver failure. Lactoferrin (Lac) is an iron-binding glycoprotein that belongs to the transferrin family. Owing to its multiple biological functions, Lac has been evaluated in a number of clinical trials to treat infections, inflammation and cancer. AIM: The present study aims to reveal a profound hepatoprotective effect of Lac, using a mouse model of Concanavalin A (Con A)-induced hepatitis, which mimics the pathophysiology of human viral and autoimmune hepatitis.
METHOD: C57Bl/6J mice were injected with bovine Lac following Con A challenge. The effects of Lac on interferon (IFN)-gamma and interleukin (IL)-4 expression were determined. The roles of Lac on T-cell apoptosis and activation, and leukocytes infiltration were examined. RESULT: The data demonstrated that the protective effect of Lac was attributed to its ability to inhibit T-cell activation and production of IFN-gamma, as well as to suppress IL-4 production by hepatic natural killer T cells.
CONCLUSION: These findings indicate a great therapeutic potential of Lac in treating in treating inflammatory hepatitis and possibly other inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20136718     DOI: 10.1111/j.1478-3231.2009.02199.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

1.  Immunomodulation of liver injury by Ascaris suum extract in an experimental model of autoimmune hepatitis.

Authors:  Wheverton C Nascimento; Roeckson P Silva; Erica S Fernandes; Maria C Silva; Gabriela C Holanda; Patrícia A Santos; Mônica P Albuquerque; Vlaudia A Costa; Nicodemos T Pontes-Filho; Valdênia O Souza
Journal:  Parasitol Res       Date:  2014-06-21       Impact factor: 2.289

2.  Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing.

Authors:  Hao Yin; Chun-Qing Song; Sneha Suresh; Qiongqiong Wu; Stephen Walsh; Luke Hyunsik Rhym; Esther Mintzer; Mehmet Fatih Bolukbasi; Lihua Julie Zhu; Kevin Kauffman; Haiwei Mou; Alicia Oberholzer; Junmei Ding; Suet-Yan Kwan; Roman L Bogorad; Timofei Zatsepin; Victor Koteliansky; Scot A Wolfe; Wen Xue; Robert Langer; Daniel G Anderson
Journal:  Nat Biotechnol       Date:  2017-11-13       Impact factor: 54.908

3.  Protective effect of interleukin-36 receptor antagonist on liver injury induced by concanavalin A in mice.

Authors:  Xiao Peng; Xiuhe Pan; Jun Tan; Yan Li; Mingcai Li
Journal:  Iran J Basic Med Sci       Date:  2020-05       Impact factor: 2.699

4.  The immunobiology of apotransferrin in type 1 diabetes.

Authors:  K Mangano; P Fagone; M Di Mauro; E Ascione; V Maiello; T Milicic; A Jotic; N M Lalic; T Saksida; I Stojanovic; C Selmi; C Farina; S Stosic-Grujicic; P Meroni; F Nicoletti
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

Review 5.  Lactoferrin in a Context of Inflammation-Induced Pathology.

Authors:  Marian L Kruzel; Michal Zimecki; Jeffrey K Actor
Journal:  Front Immunol       Date:  2017-11-06       Impact factor: 7.561

6.  The protective effect of intrasplenic transplantation of Ad-IL-18BP/IL-4 gene-modified fetal hepatocytes on ConA-induced hepatitis in mice.

Authors:  Xueting Shao; Yun Qian; Chenhuai Xu; Bo Hong; Wanhong Xu; Ling Shen; Changzhong Jin; Zhigang Wu; Xiangmin Tong; Hangping Yao
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

Review 7.  Potential Use of Biological Proteins for Liver Failure Therapy.

Authors:  Kazuaki Taguchi; Keishi Yamasaki; Hakaru Seo; Masaki Otagiri
Journal:  Pharmaceutics       Date:  2015-08-31       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.